- Published on
Pharmacology - Abciximab
The action of abciximab
It prevents platelets from becoming activated.
Method of Operation
When it comes to the platelet GP IIb/IIIa receptor, abciximab is a monoclonal antibody Fab fragment targeting the receptor. Platelet aggregation is prevented as a result of its ability to attach to and inactivate the receptor, which in turn prevents the binding of fibrinogen.
Administered through intravenous injection. Half life ten to thirty minutes.
Use in Clinical Settings
In high-risk patients who are undergoing coronary angioplasty, which is a surgery to unblock coronary arteries, this medication is administered in addition to heparin and aspirin. It protects against both restenosis and reinfarction.
Thrombocytopenia and bleeding are examples of adverse reactions.
For the usage of specialists. Only used once due to the immunogenicity of the substance. Eptifibatide, a peptide sequence derived from a GPIIb/IIIa receptor ligand, is a drug that has a comparable mechanism of action.
The action of abciximab
It prevents platelets from becoming activated.
Method of Operation
When it comes to the platelet GP IIb/IIIa receptor, abciximab is a monoclonal antibody Fab fragment targeting the receptor. Platelet aggregation is prevented as a result of its ability to attach to and inactivate the receptor, which in turn prevents the binding of fibrinogen.
Administered through intravenous injection. Half life ten to thirty minutes.
Use in Clinical Settings
In high-risk patients who are undergoing coronary angioplasty, which is a surgery to unblock coronary arteries, this medication is administered in addition to heparin and aspirin. It protects against both restenosis and reinfarction.
Thrombocytopenia and bleeding are examples of adverse reactions.
For the usage of specialists. Only used once due to the immunogenicity of the substance. Eptifibatide, a peptide sequence derived from a GPIIb/IIIa receptor ligand, is a drug that has a comparable mechanism of action.
0 Comments
